Adiponectin as an insulin sensitizer and a negative regulator of angiogenesis mainly secreted from visceral adipose tissue, has been shown to inhibit colorectal cancer in animal experiments and has been related to colorectal cancer risk in clinical trials [19]. Here, ADIPOQ is linked to colorectal cancer.